SCHEMBL3531018

SCHEMBL3531018

CC(C)COC(=O)C1CCN(c2nccc(Cl)n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 1/20 0.49
MAPT P10636 2/20 0.46
ALDH1A1 P00352 8/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PTPN11 Q06124 1/20 0.41
KDM4E B2RXH2 9/20 0.41
KMT2A Q03164 3/20 0.41
HSD17B10 Q99714 3/20 0.41
HPGD P15428 2/20 0.41
MAPK1 P28482 1/20 0.41
MEN1 O00255 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP2C19 P33261 2/20 0.40
POLB P06746 1/20 0.40
LMNA P02545 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530584 0.81 PANK3 (0.59) PANK3MAPTALDH1A1PTPN11KDM4E
SCHEMBL12289389 0.76 CYP3A4 (0.50) PANK3ALDH1A1NPSR1KDM4EKMT2A
SCHEMBL31402771 0.72 SMO (0.50) PANK3MAPTALDH1A1PTPN11KDM4E
SCHEMBL31402773 0.72 SMO (0.50) PANK3MAPTALDH1A1PTPN11KDM4E
SCHEMBL4608418 0.71 PANK3 (0.41) PANK3ALDH1A1NPSR1PTPN11KDM4E
SCHEMBL3532348 0.71 FAAH (0.45) MAPTALDH1A1TSHRNPSR1KDM4E
SCHEMBL20367372 0.71 PANK3 (0.45) PANK3ALDH1A1KDM4EKMT2AHSD17B10
SCHEMBL4752799 0.71 PANK3 (0.45) PANK3
SCHEMBL18166973 0.70 PANK3 (0.46) PANK3ALDH1A1TSHRNPSR1PTPN11
SCHEMBL195417 0.70 KDM4E (0.60) MAPTALDH1A1TSHRNPSR1PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels KCNJ1, KCNJ2, KCNJ11 PANK3 897/4885MAPT 2601/4885ALDH1A1 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.